Search Results

ONK Therapeutics (“ONK”) and NAYA Biosciences Inc. (“NAYA”) today announced that they have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK™ bispecific antibodies.

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA’s FLEX-NK™ bispecific antibodies.

ONK Therapeutics Ltd announced that the European Patent Office has granted its licensed patent covering CISH knockout in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells.

ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer cell therapies to cure patients with cancer, announced the appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer.

Together, Intellia and ONK hope to develop, engineer and test new allogeneic CRISPR-edited NK cell therapies.

ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.

ONK Therapeutics announced the first in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy.

Dr. Reine brings significant experience to ONK Therapeutics’ Board from both the life sciences industry and in financial services.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced a licensing and collaboration agreement.

ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Mary Reilly as Chief Operating Officer (COO).